Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study

医学 淋巴血管侵犯 外科肿瘤学 危险系数 内科学 放化疗 食管鳞状细胞癌 倾向得分匹配 肿瘤科 腹部外科 食管癌 回顾性队列研究 比例危险模型 外科 胃肠病学 癌症 置信区间 转移
作者
Yoshinobu Yamamoto,Ryu Ishihara,Hirofumi Kawakubo,M. Nishikawa,Sachiko Yamamoto,Tomohiro Kadota,Seiichiro Abe,Masao Yoshida,Tsutomu Tanaka,Hiroaki Nagano,Hiroyoshi Nakanishi,Tetsuya Yoshizaki,Kotaro Waki,Akiko Takahashi,Yoshiyasu Kitagawa,Ken‐ichi Mizuno,Kenro Kawada,Yoshiyasu Kono,Chikatoshi Katada,Takashi Hashimoto,Yasuaki Nagami,Toshiyuki Yoshio,Toshio Shimokawa,Keiji Nihei,Kazuo Koyanagi,Ken Kato,Tomonori Yano,Manabu Muto,Yuko Kitagawa
出处
期刊:Journal of Gastroenterology [Springer Science+Business Media]
标识
DOI:10.1007/s00535-024-02188-7
摘要

Abstract Background Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered. Methods This was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence. Results Among 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group. Conclusions In patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包应助Qawsed采纳,获得10
2秒前
3秒前
却姓杨发布了新的文献求助10
4秒前
Jiuu发布了新的文献求助10
4秒前
经纲完成签到 ,获得积分0
5秒前
科目三应助wjw采纳,获得10
6秒前
单身的翼完成签到,获得积分10
6秒前
8秒前
Othinus完成签到,获得积分10
8秒前
8秒前
神烦狗发布了新的文献求助10
9秒前
彭于晏应助ffei采纳,获得10
10秒前
卡比兽mini完成签到 ,获得积分10
11秒前
11秒前
欣喜若魔完成签到,获得积分10
12秒前
13秒前
13秒前
sxyc5发布了新的文献求助20
13秒前
bkagyin应助神烦狗采纳,获得10
14秒前
遇晴发布了新的文献求助10
14秒前
太叔捕完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
17秒前
molihuakai应助whuhustwit采纳,获得10
17秒前
Hui完成签到,获得积分10
18秒前
蝴蝶兰发布了新的文献求助10
18秒前
19秒前
欣喜若魔发布了新的文献求助20
19秒前
19秒前
amanda发布了新的文献求助30
20秒前
东东发布了新的文献求助10
20秒前
ll发布了新的文献求助10
20秒前
张8完成签到,获得积分20
21秒前
梦M发布了新的文献求助10
21秒前
Qawsed发布了新的文献求助10
23秒前
清欢完成签到 ,获得积分10
23秒前
海边的曼彻斯特完成签到 ,获得积分10
24秒前
乂氼完成签到 ,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 2500
Roms fliessende Grenzen : Archäologische Landesausstellung Nordrhein-Westfalen 1000
Atlas of Aligner Treatment and Planning A Case-Based Approach 1000
Geist der Kunst und Kultur 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7425734
求助须知:如何正确求助?哪些是违规求助? 9028784
关于积分的说明 19232976
捐赠科研通 7054352
什么是DOI,文献DOI怎么找? 3235704
关于科研通互助平台的介绍 2399165
邀请新用户注册赠送积分活动 2218285